BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
President Donald Trump’s approval rating ticked up slightly in two weekly polls and was down half a point in a third as the government shutdown stretches into a fourth week with no clear path to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback